(12) **Translation of European patent specification**

(11) **NO/EP 2632467 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 487/14 (2006.01)
A61K 31/519 (2006.01)
A61P 35/00 (2006.01)
C07D 487/20 (2006.01)
C07D 519/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.11.07
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.06.22
(86)	European Application Nr.	11838545.9
(86)	European Filing Date	2011.10.25
(87)	The European Application's Publication Date	2013.09.04
(30)	Priority	2010.10.25, US, 406498 P
(84)	Designated Contracting States	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	G1 Therapeutics, Inc., 79 T.W. Alexander Drive 4401 Research Commons, Suite 105, Research Triangle Park, NC 27709, US-USA
(72)	Inventor	TAVARES, Francis, X., c/o G-Zero Therapeutics, Inc.450 West Drive; CB No.7295, Chapel Hill,NC 27599-7295, US-USA STRUM, Jay C., c/o G-Zero Therapeutics, Inc.450 West Drive; CB No.7295, Chapel Hill,NC 27599-7295, US-USA
(74)	Agent or Attorney	Oslo Patentkontor AS, Postboks 7007 Majorstua, 0306 OSLO, Norge

(54) Title **CDK INHIBITORS**

(56) References Cited

WO-A1-2010/020675
WO-A1-2013/148748
WO-A2-2005/052147

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Forbindelse med formel Ia:



eller med formel Ib:



eller med formel Ic:



eller med formel Id:



eller med formel Ie:



eller med formel If:



eller med formel Ig:



eller med formel Ih:



eller med formel Ii:



eller med formel Ij:



eller et farmasøytisk akseptabelt salt derav

hvor R er H, C_1-C_3-alkyl eller halogenalkyl;

hver R^1 er uavhengig aryl, alkyl, cykloalkyl eller halogenalkyl, hvor hver av nevnte alkyl, cykloalkyl og halogenalkylgrupper valgfritt omfatter O- eller N-heteroatomer i stedet for et karbon i kjeden og to R^1 på tilstøtende

ringatomer eller på samme ringatom sammen med ringatomet/ringatomene som de er bundet til valgfritt danner en 3- til 8-leddet cyklus;

y er 0, 1, 2, 3 eller 4;

hver X er uavhengig CH eller N; og

R^2 er valgt fra strukturene:




















NH
OH
alkyl
F
NH2
OMe
HN
O



hvor begrepet "aryl", alene eller i kombinasjon, betyr et karbocyklisk aromatisk system som inneholder én eller to ringer, hvor slike ringer kan være bundet sammen på kondensert måte og hvor hvilket som helst aryl kan ha 1 eller flere substituenter uavhengig valgt fra C_1-C_6-alkyl, hydroksyl, halogen, halogenalkyl, nitro, cyano, alkoksy og C_1-C_6-alkylamino.

2. Forbindelse ifølge krav 1 som har formel Ii:



eller et farmasøytisk akseptabelt salt derav.

3. Forbindelse ifølge krav 1 eller 2, hvor begge X er N.

4. Forbindelse ifølge et av de forutgående krav, hvor R er hydrogen eller C_1-C_3 alkyl.

5. Forbindelse ifølge hvilket som helst av kravene 1 til 4, hvor R^2 er:

(a)  ; eller

(b)  ; eller

(c)  ; eller

(d) 

6. Forbindelse ifølge krav 1 eller 2 som har formel:

 ,

eller et farmasøytisk akseptabelt salt derav.

7. Forbindelse ifølge krav 1 eller 2 som har formel:



eller et farmasøytisk akseptabelt salt derav.

8. Forbindelse ifølge krav 1 eller 2, med formel Ii:



hvor R er H

eller et farmasøytisk akseptabelt salt derav.

9. Forbindelse ifølge krav 8 som har formel:



eller et farmasøytisk akseptabelt salt derav.

10. Forbindelse ifølge krav 8 som har formel:



,

eller et farmasøytisk akseptabelt salt derav.

11. Forbindelse ifølge krav 1 valgt fra strukturene:



,



,



,


,


,


,


,


,


,


,

5


,

og



12. Forbindelse ifølge krav 1 valgt fra strukturene:


,


,


,


,


,

,

,

,

,

,

og


5 **13.** Forbindelse ifølge krav 1 valgt fra strukturene:


,

,


,

,

,

,

,

,

,

5 ,



,

og



14. Forbindelse ifølge krav 1 valgt fra strukturene:



,



, , ,


,

,

,

,

,

og



5

15. Forbindelse ifølge hvilket som helst av kravene 1 til 14, hvor forbindelsen eller det farmasøytisk akseptable salt derav er i form av en fast, halvfast eller flytende doseringsform.

16. Farmasøytisk sammensetning som omfatter en virksom mengde av en forbindelse ifølge hvilket som helst av kravene 1 til 14 eller et farmasøytisk akseptabelt salt derav.